Document is current
Any future updates will be listed below
-
Authors
Hanin, Aurélie https://orcid.org/0000-0002-5912-9998
Denis, Jérôme Alexandre https://orcid.org/0000-0002-1617-4617
Frazzini, Valerio https://orcid.org/0000-0003-1187-3352
Cousyn, Louis https://orcid.org/0000-0003-1407-5575
Imbert-Bismut, Françoise
Rucheton, Benoit https://orcid.org/0000-0002-5893-6595
Bonnefont-Rousselot, Dominique https://orcid.org/0000-0003-4689-9202
Marois, Clémence https://orcid.org/0000-0002-3266-0623
Lambrecq, Virginie https://orcid.org/0000-0001-9442-0302
Demeret, Sophie https://orcid.org/0000-0002-0523-6472
Navarro, Vincent https://orcid.org/0000-0003-0077-8114
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-IAIHU-06)
Fondation Recherche Médicale (FDM20170839111)
Fondation Assitance Publique-Hôpitaux de Paris (EPIRES- Marie Laure PLV Merchandising)
- License Information
-
More Information
Article History
Received: 1 December 2021
Revised: 29 January 2022
Accepted: 30 January 2022
First Online: 21 February 2022
Declarations
:
: Vincent Navarro reports personal fees from UCB Pharma, EISAI, GW Pharma and LivaNova, outside the submitted work. Sophie Demeret reports individual payment from UCB Pharma, Regeneron and ARGENX. The other authors report no disclosures.
: The protocol was approved by our local (2012, CPP Paris-VI) and by the INSERM ethic committees (C16-16, 20152482). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: Patients or relatives were informed and give their consent.
: Patients or relatives were informed and give their consent.
